日批在线视频_内射毛片内射国产夫妻_亚洲三级小视频_在线观看亚洲大片短视频_女性向h片资源在线观看_亚洲最大网

US EUROPE AFRICA ASIA 中文
Business / Companies

Xi'an Janssen plans 10 drug launches in four areas by 2020

By Wang Wen (China Daily) Updated: 2015-10-31 09:50

Xi'an Janssen Pharmaceutical Ltd, Johnson & Johnson Services Inc's largest subsidiary in China, plans to launch more than 10 new medicines in China by 2020.

Kris Sterkens, chairman of Jassen Asia Pacific, said innovation remains its core strategy, and its products will be spread over four main treatment areas: tumors, the autoimmune system, mental health and infectious and metabolic diseases such as hepatitis and diabetes.

The firm's new-product strategy, he said, was being supported by a number of recent findings that showed China has strong demand for medicine targeted at those diseases.

A survey by the Economist Intelligence Unit, a global business intelligence belonging to the Economist Group, for instance, analyzed markets in five countries across Asia Pacific including China, and reached the conclusion that "the region now carries a huge global burden of non-communicable diseases, such as cancer and mental illness".

As many as 85 percent of deaths in China in 2010 were the result of non-communicable diseases, according to the report, with cancer, cardiovascular disease and diabetes topping the list of causes.

"Healthcare systems in Asia Pacific are struggling to manage the rise in non-communicable diseases and the shift to long-term treatment of chronic conditions," said Charles Ross, the survey report's editor.

Following on from those and other findings, Xi'an Janssen will launch a new product for prostate cancer soon, said Sterkens. Research is also being conducted on a diabetes medicine.

Xi'an Janssen has launched 14 major new products in the past five years aimed at treating conditions like human immunodeficiency virus, cancer and mental illness.

Established 30 years ago, it has been a regular investor in China since its launch.

A new $290 million plant in Xi'an will be in operation from 2018, said Cesar Rodriguez, the company's chief.

The new site will have an annual capacity of 280 million medicine packages, which will be sold around the world, said Rodriguez.

Xi'an Janssen is well known in China for over-the-counter drugs such as Domperidone and Daktarin.

Johnson & Johnson combined its OTC business in China last year with Xi'an Janssen, a controversial move at the time with some industry commentators fearing the integration might hurt sales.

Rodriguez insisted the integration, named One China OTC, has achieved strong results, although he refused to detail exact numbers.

Hot Topics

Editor's Picks
...
主站蜘蛛池模板: 成人毛片在线精品国产 | 9.1片黄在线观看 | 国产精品mv | 久久中文字 | 日韩影视一区二区三区 | 国产亚洲欧美一区二区 | 国产精品超碰 | 日本精品一区二区 | 亚洲精品久久久久久久久久久久久 | 成年人国产视频 | 亚洲性在线| 日韩激情第一页 | 免费的av网址 | 欧美一级一区 | 成年人在线观看网站 | 香蕉av在线播放 | 欧美日韩一级在线 | 国产精品视频免费观看 | 精品美女久久 | 五月激情啪啪 | 欧美偷拍视频 | 色天堂影院| 4色av | 人成精品 | 看毛片视频 | 日本精品视频在线观看 | 亚洲精品亚洲人成人网 | 香蕉视频你懂的 | 激情综合五月天 | 午夜一级大片 | 三级精品视频 | 欧美三级久久 | 精品999视频 | 亚洲视频一区二区 | 精品国产一区二区三区在线观看 | 日韩在线视频观看免费 | 日日夜夜撸撸 | 成人午夜免费在线观看 | 婷婷国产视频 | 在线观看成人免费视频 | av午夜精品 |